Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Fusion protein Stories

Algae Could One Day Help Fight Cancer
2012-12-10 15:08:04

[ Watch the Video: Biology Helping To Engineer Drugs ] Connie K. Ho for redOrbit.com — Your Universe Online Pond scum may be undervalued, but a team of scientists recently discovered it could have biological value. Researchers from the University of California, San Diego (UCSD) recently revealed that they have successfully genetically engineered algae that can make a complex, therapeutic drug that is anti-cancer. The researchers believe that the results of the experiment allow...

2012-11-13 08:35:36

THOUSAND OAKS, Calif. and BRYAN, Texas, November 13, 2012 /PRNewswire-iReach/ -- ImmunGene, Inc. (ImmunGene) and Caliber Biotherapeutics, LLC (Caliber) announced today the launch of Valor Biotherapeutics, LLC (Valor), a joint venture focused on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers. The mAb-IFN fusion protein technology was invented in Professor Sherie Morrison's laboratory at the...

2012-08-13 06:24:49

PRINCETON, N.J., Aug. 13, 2012 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with its client, ZZ Biotech, on process development and production of a new potential therapeutic for ischemic stroke. The drug, known as 3K3A-APC, is a form of activated human Protein C whose molecular structure has been intentionally modified to remove the undesirable side effect of bleeding. ZZ Biotech recently announced the start of Phase 1 trials with this material....

Genetic Cause Of Most Lethal Brain Tumor Discovered-- Could Lead To New Treatment
2012-07-26 13:46:21

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes. The study also found that drugs that target the protein produced by this genetic aberration can dramatically slow the growth of glioblastomas in mice. The findings were published today in the online edition of the journal Science. "Our findings are doubly important," said study...

2012-06-18 16:32:54

Alfonso Valencia's group discover proteins made by combining different genes in healthy cells and tissues To date this has been considered a rarity confined to anomalous processes like cancer The authors believe their finding opens a new line of research inquiry with multiple implications in Human Genomics and cancer Sequencing the human genome was just the first step. The next challenge is of the kind that makes history: to decode the genome, and understand how the information...

2012-06-06 02:25:48

SAN DIEGO, June 6, 2012 /PRNewswire/ -- PacificGMP (San Diego, California), the leader in single-use bioprocessing for development and manufacturing for its client partners, and Vasgene Therapeutics (Los Angeles, California), a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology, today announced the successful completion of large scale cGMP manufacture of Vasgene's recombinant fusion...

2012-06-04 02:26:37

PLANTATION, Fla. and HOUSTON, June 4, 2012 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and The University of Texas MD Anderson Cancer Center jointly announce a collaboration for process development and GMP manufacturing of a fusion protein composed of a vascular endothelial growth factor (VEGF) and the recombinant toxin, Gelonin (rGel), conjugated to a DOTA chelator. The fusion protein targets the tumor neovasculature, or blood supply, and inhibits tumor growth, and the...

2012-05-29 10:24:01

NANTES, France, May 29, 2012 /PRNewswire-iReach/ -- Grant of a major patent from the European patent office BIO 2012: Fostering partnership contacts on the interleukin-15 fusion protein (CYP0150) and the innovative and proprietary conjugated monoclonal antibody-cytokine platform Achievements: Strengthened the superior pharmacology/safety profile of CYP0150 relative to IL-2 Achieved and validated the transition of CYP0150's biomanufacturing to industrial standards Further...

2012-04-10 02:26:17

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch(TM) technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated...

2012-04-04 06:27:24

TORONTO, April 4, 2012 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company developing proprietary and innovative biologic therapies, today provided an update on its lead cancer program - a SIRPaFc fusion protein targeting the CD47 pathway. Trillium's SIRPaFc development candidate is a proprietary antibody-like fusion protein that blocks the activity of CD47, a molecule upregulated on many leukemias and solid tumors. CD47 binds to SIRPa on the...